- Exchanges
- BSE, NSE
- Industry
- Pharmaceuticals
- Issue
- Book building
Mankind Pharma IPO
₹1,424.05
+31.86% on listing
Listing-day close · BSE · 9 May 2023 · issue price ₹1,080
Mankind Pharma’s ₹4,326 crore IPO was priced at ₹1,080 a share. It listed on the BSE on 9 May 2023 and closed its first day at ₹1,424.05, up 31.86% on the issue price.
Timeline
- Opens
- Closes
- Allotment
- Refunds
- Shares in demat
- Listing
Issue details
- Issue size
- ₹4,326 Cr
- Fresh issue
- —
- Offer for sale
- ₹4,326 Cr
- Lot size
- 13 shares
- Minimum investment
- ₹14,040
- Face value
- ₹1
- Registrar
- Kfin Technologies
Subscription
| Category | Shares offered | Times subscribed |
|---|---|---|
| Total | — | 11.01× |
Overall, from the basis of allotment.
Financials and valuation
- Market cap (post-issue)
- ₹43,264 Cr
- P/E (post-issue)
- 31.9
- EPS (post-issue)
- ₹33.82
- Price to book
- 7.0
- ROE
- 27.60%
- ROCE
- 26.10%
- PAT margin
- 18.67%
- Promoter holding
- 79.00% → 76.50%
Financials as of 31 Mar 2022, from the offer documents.
Listing
- Listing date
- 9 May 2023
- Issue price
- ₹1,080
- Open
- ₹1,300.00
- High
- ₹1,430.00
- Low
- ₹1,300.00
- Close
- ₹1,424.05
Listing day on the BSE. The close was +31.86% on the issue price.
MANKIND share price todayFAQs
When did the Mankind Pharma IPO open and close?
It opened on 25 Apr 2023 and closed on 27 Apr 2023.
What was the Mankind Pharma IPO price?
The price band was ₹1,026–1,080 a share. The final issue price was ₹1,080.
What is the lot size and minimum investment?
One lot is 13 shares, ₹14,040 at ₹1,080 a share. Retail investors apply in whole lots.
How much did Mankind Pharma raise?
₹4,326 crore: ₹4,326 crore offered by existing shareholders.
How many times was the Mankind Pharma IPO subscribed?
11.01 times overall.
How did Mankind Pharma list?
It listed on the BSE on 9 May 2023 at ₹1,300.00 and closed the day at ₹1,424.05, up 31.86% on the ₹1,080 issue price.
Who is the registrar of the Mankind Pharma IPO?
Kfin Technologies handles the allotment, refunds and credit of shares.
For information only. Not investment advice or a research report.
Full disclaimerSee how an IPO fits your plan
Armor checks every holding against your goals, risk and timeline.
Get the app